Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News Corcept Therapeutics (NASDAQ: CORT) puts resistant hypertension in the cortisol spotlight with new MOMENTUM trial data Corcept Therapeutics says 27.3% of resistant hypertension patients may have hypercortisolism. Read what the MOMENTUM data could mean next. byPallavi MadhirajuMarch 29, 2026